VWM
SVA

Valley Wealth Managers’s Sinovac Biotech, Ltd SVA Stock Holding History

Valley Wealth Managers’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-100
Closed -$1K – 269
2016
Q4 		$1K Buy
+100
New +$601 ﹤0.01% 259

Other funds holding SVA

SA
SAIF Advisors Admiralty, Hong Kong $438M AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Valley Wealth Managers's SVA Position: Q1 2017 in Review

Valley Wealth Managers sold out of Sinovac Biotech, Ltd (SVA) in Q1 2017, closing a stake of 100 shares — an estimated $1K sold.

Valley Wealth Managers first reported a position in SVA in Q4 2016 and held it in 1 quarter. The position peaked at $1K in Q4 2016. 35 funds tracked by Wall St. Rank hold SVA as of Q1 2017.

  • Valley Wealth Managers reported no remaining Sinovac Biotech, Ltd position as of Q1 2017 after selling out during the quarter.
  • Valley Wealth Managers sold 100 Sinovac Biotech, Ltd shares in Q1 2017, an estimated $1K.
  • Valley Wealth Managers first reported a position in Sinovac Biotech, Ltd in Q4 2016 and held it in 1 quarter.
  • Valley Wealth Managers's Sinovac Biotech, Ltd position peaked at $1K in Q4 2016.
  • 35 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2017.

Based on Valley Wealth Managers's 13F filing for Q1 2017, filed 12 May 2017.